Drug Trial Radar · NCT05514535
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
Last checked: Nov 20, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
573
Actual
Start
Aug 29, 2022
Primary completion
Mar 5, 2025
Study completion Apr 9, 2025
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Aug 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes. The study looks at how well the study medicines control blood glucose levels. Participants will either get semaglutide together with a lower dose of insulin glargine or a higher dose of insulin glargine. The study will last for about 47 weeks (approximately 11 months). Participants will have 9 clinic visits, 15 phone/video calls and 1 home visit. Participants will be asked to wear a sensor that measures their blood sugar all the time in 2 periods of 10 days during the study.
Conditions
- Diabetes Mellitus, Type 2
- Obesity
Interventions
SemaglutideDrug
Participants will receive once-weekly semaglutide s.c. for 40 weeks. Semaglutide 0.25 mg will be given at week 0 and then the dose will be escalated at weeks 4, 8 and 12 to 0.5 mg, 1 mg, 2 mg respectively.
Insuline glargine U100 (reduced)Drug
Participants will receive insulin glargine U100 s.c. once-daily. Insulin glargine dose will be reduced by 10 U at initiation of semaglutide and then again at each semaglutide dose escalation up to 40 weeks. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.4-7.2 mmol/L).
Insuline glargine U100 (titrated)Drug
Participants will receive titrated insulin glargine U100 s.c. once-daily up to 40 weeks. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.4-7.2 mmol/L).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Glycated Haemoglobin (HbA1c) [Noninferiority]Time frame: From baseline (week 0) to end of treatment (week 40)
Locations
239 sites in 12 countries. Site status is shown where the registry gives one.
Shoals Primary Care
Sheffield, Alabama
Lenzmeier Fam Med CCT Research
Glendale, Arizona
Synexus Clinical Research US, Inc./Desert Clinical Research,
Mesa, Arizona
OneLife Direct Care Inc.
Searcy, Arkansas
Unity Health-Searcy Medical Center
Searcy, Arkansas
San Fernando Valley Hlth Inst, LLC
Canoga Park, California
Velocity Clin Res-Chula Vista
Chula Vista, California
John Muir Physicians Network
Concord, California
Valley Research
Fresno, California
Ascada Research
Fullerton, California
Providence Medical Foundation
Fullerton, California
Velocity Clinical Research Huntington Park
Huntington Park, California
Scripps Memorial Hospital La Jolla
La Jolla, California
Velocity Clin Res San Diego
La Mesa, California
First Valley Medical Group
Lancaster, California
Loma Linda Univ Hlth Cr Endo
Loma Linda, California
Torrance Clin Res Inst, Inc.
Lomita, California
NRC Research Institute
Los Angeles, California
Downtown LA Res Ctr. Inc.
Los Angeles, California
Velocity Clin Res Los Angeles
Los Angeles, California
Valley Clinical Trials, Inc.
Northridge, California
San Diego Family Care_San Diego
San Diego, California
Wetlin Research Associates, Inc.
San Diego, California
University Clin Investigators
Tustin, California
Velocity Clin Res, Denver
Denver, Colorado
Chase Medical Research LLC
Waterbury, Connecticut
Indago Research & Health Center Inc.
Hialeah, Florida
Encore Medical Research LLC
Hollywood, Florida
Northeast Res Inst. Inc.
Jacksonville, Florida
Jacksonville Ctr For Clin Res
Jacksonville, Florida
Care-Partners-Clinical-Research, LLC
Jacksonville, Florida
Suncoast Research Group, LLC
Miami, Florida
New Horizon Research Center
Miami, Florida
Elite Research Center
Miami, Florida
Diverse Clinical Research Miami
Miami, Florida
Reyes Clinical Research, Inc
Miami, Florida
International Research Associates, LLC_Miami
Miami, Florida
South Broward Research LLC
Miramar, Florida
Suncoast Clin Res Port Richey
New Port Richey, Florida
Suncoast Clinical Research, Inc._New Port Richey
New Port Richey, Florida
Showing 40 of 239 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.